Pretreatment Serum Level of Testosterone as a Prognostic Factor in Japanese Men with Hormonally Treated Stage D2 Prostate Cancer.

Igarashi, Takashi; Suzuki, Hiroyoshi; Akakura, Koichiro; Komiya, Akira; Nakamachi, Hiroshi; Ichikawa, Tomohiko; Igarashi, Tatsuo; Itô, Haruo

doi:10.1507/endocrj.48.573

Cited by 63 publications

(35 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In accordance with Imamoto et al (222 patients), the same authors noted that pretreatment TT were associated with an increased progression-free survival (respectively p=0.035 and p=0.023) 38,39 .…”

Section: Incidencesupporting

confidence: 82%

The Relationship between Total Testosterone Levels and Prostate Cancer: A Review of the Continuing Controversy

2015

View full text Add to dashboard Cite

The relationship between total testosterone and prostate cancer has been an area of interest among physicians for decades. Conflicting results have been reported on the relationship between total testosterone and subsequent prostate cancer. Much of this controversy appears to be based on conflicting study designs, definitions and methodologies. To date no prospective study with sufficient power has been published to unequivocally resolve the issue. The preponderance of studies of the safety of exogenous testosterone in men with a prostate cancer history suggests that there is little if any risk. However, because the risk has not proved to be zero, the most prudent course is to follow such men with regular prostate specific antigen measurements and digital rectal examinations.

show abstract

Section: Incidencesupporting

confidence: 82%

The Relationship between Total Testosterone Levels and Prostate Cancer: A Review of the Continuing Controversy

2015

View full text Add to dashboard Cite

show abstract

“…Three previous studies (33)(34)(35), of which two had small sample sizes (34,35), have investigated this association in patients with metastatic PCa patients. Consistent with the present study, the results of these studies indicated that lower testosterone levels predicted poor overall (33,34) and progression-free (35) survival times in patients with metastatic PCa.…”

Section: Discussionmentioning

confidence: 99%

Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer

Meng

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Abstract. Serum testosterone is a potential marker to distinguish between indolent and aggressive prostate cancer (PCa). The present study aimed to investigate whether low levels of total serum testosterone at diagnosis were associated with aggressive PCa and poor clinical outcomes. In total, 762 non-Hispanic Caucasian men with previously untreated PCa were recruited from The University of Texas MD Anderson Cancer Center (Houston, TX, USA). Patients were categorized into three groups based on their total serum testosterone levels according to clinical guidelines [low (<230 ng/dl), intermediate (230-350 ng/dl) and normal (>350 ng/dl)]. PCa aggressiveness (low-, intermediate-or high-risk, or metastatic) was compared using multinomial logistic regression. Rates of disease progression, mortality from any cause and PCa-specific mortality were compared using the multivariate Cox proportional hazards model. Testosterone levels significantly decreased as PCa aggressiveness increased (P<0.001). Compared with the normal testosterone group, the low testosterone group had 2.9-fold (OR, 2.92; 95% CI, 1.74-4.90; P<0.001), 5.6-fold (OR, 5.63; 95% CI, 3.14-10.12; P<0.001) and 72.4-fold (OR, 72.40; 95% CI,; P<0.001) increased risks of having intermediate-risk, high-risk and metastatic PCa, respectively. Furthermore, low levels of testosterone were significantly associated with a 10.7-fold (HR, 10.68; 95% CI, 1.35-84.44; P= 0.03) increased risk of PCa-specific mortality. The results of the present study indicate that low levels of total serum testosterone at diagnosis are associated with aggressive PCa and predict poor PCa-specific survival.

show abstract

“…We have previously reported that, in Japanese patients with hormonally treated metastatic prostate cancer, the patients with higher pretreatment testosterone levels had signifi cantly better cause-specifi c and progression-free survivals. 36 A single gene of more than 90 kb on Xq11-12 encodes the androgen receptor. This protein has androgen-and DNA-binding domains, as well as an Nterminal domain that performs a modulatory function.…”

Section: Biomarkers To Predict Hormone Therapy Responsementioning

confidence: 99%

Current topics and perspectives relating to hormone therapy for prostate cancer

et al. 2008

Self Cite

View full text Add to dashboard Cite

Prostate cancer is androgen-dependent, and hormone therapy, mainly achieved by androgen deprivation, has been one of the main treatment modalities in the clinical management of prostate cancer patients for more than six decades. In the 1980s, luteinizing hormone-releasing hormone agonists, which reduce testosterone to castration levels, were introduced Also, after the 1980s, nonsteroidal antiandrogens were developed in addition to steroidal antiandrogens. Since then, so-called maximum androgen blockade (MAB)/combined androgen blockade (CAB), which is a combination of surgical or medical castration and oral antiandrogens, has been developed. More recently, novel treatment modalities have been developed, such as intermittent androgen suppression, nonsteroidal antiandrogen monotherapy, and alternative antiandrogen therapy after relapse from initial MAB/CAB, The present article focuses on these treatment modalities to review current topics and perspectives with respect to hormone therapy for prostate cancer.

show abstract

Pretreatment Serum Level of Testosterone as a Prognostic Factor in Japanese Men with Hormonally Treated Stage D2 Prostate Cancer.

Cited by 63 publications

References 26 publications

The Relationship between Total Testosterone Levels and Prostate Cancer: A Review of the Continuing Controversy

The Relationship between Total Testosterone Levels and Prostate Cancer: A Review of the Continuing Controversy

Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer

Current topics and perspectives relating to hormone therapy for prostate cancer

Contact Info

Product

Resources

About